Bioactive Products
| A unique collection of 223 Neuroprotection natural compounds for high throughput screening (HTS) | ||
| Catalog No: | B72a21 | Neuroprotection Compound Library Screening Details |
| Size: | 1mg/well * 223 Compounds 2mg/well * 223 Compounds | |
| Cat. No. | Information |
| CFN90238 | 3,4,5-Tricaffeoylquinic acid 3,4,5-Tricaffeoylquinic acid may attenuate the TNF-α- and LPS-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor 4 expression-mediated activation of the Akt, ERK and NF-ĸB pathways, it may exert an inhibitory effect against the pro-inflammatory mediator-induced skin disease. 3,4,5-Tricaffeoylquinic acid may attenuate the proteasome inhibitor-induced programmed cell death in PC12 cells by suppressing the activation of the mitochondrial pathway and the caspase-8- and Bid-dependent pathways, the effect be attributed to its inhibitory effect on the formation of reactive oxygen species and depletion of GSH. |
| CFN90240 | Tangeretin Tangeretin is a Notch-1 inhibitor, has antiproliferative, antiinvasive, antimetastatic and antioxidant activities.Tangeretin has therapeutic potential for melanoma and melanoma-associated depigmentation, because it can induce hyperpigmentation through the activation of melanogenic signaling proteins and initiation of sustained ERK2 expression. |
| CFN90308 | Acetylshikonin Acetylshikonin can effectively inhibit tumor cells, it can be used to treat hepatocellular carcinoma cells expressing hepatitis B virus X protein (HBX) by inducing ER stress , an oncoprotein from hepatitis B virus. Acetylshikonin inhibits the production of eicosanoid, is due to the attenuation of cytosolic phospholipase A(2) membrane recruitment via the decrease in [Ca(2+)](i) and to the blockade of cyclooxygenase and 5-lipoxygenase activity. |
| CFN90315 | Breviscapine Breviscapine can reduce the inflammatory response, protect the lungs from inflammatory cascade responses by inhibiting the expression of IL-18 and ICAM-1. Breviscapine inhibits the increased levels of 4-HNE and 8-OHdG, and enhances the antioxidant capacity of cortex tissue. Breviscapine can treat coronary disease, breviscapine injection significantly ameliorates neurologic deficit, reduces infarct volume and water content, and suppresses the levels of NSE in a time-dependent manner, may the mechanism is by up-regulating the expression of Nrf2/HO-1 pathway . |
| CFN90370 | Tanshinol B Reference standards. |
